Latest News

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

OSAKA, Japan–(BUSINESS WIRE)–Takeda acquired PvP Biologics following a Phase 1 study of investigational medicine TAK-062 for the treatment of uncontrolled celiac disease.

Source link

Related posts

Is Medical Pot a Blessing for Seniors?


Listen: Pharma’s response to coronavirus, Google’s appetite for health data, and biotech’s rise in China


Stereotypes About Girls and Math Don't Add Up, Scans Show


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy